ArticleJAMA oncology2018

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply.

Inmaculada Hernandez et al.PubMed ↗Publisher ↗

No numbers read from the abstract.